


PRELIMINARY AMENDMENT
National Stage Entry of PCT/JP03/08785
Attorney Docket No.: Q85706

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (original): A galactosamine derivative represented by the following formula (1):



wherein R₁, R₂ and R₅ each independently represents SO₃⁻ or H, and at least one of them represents SO₃⁻;

R₃ represents H, acetyl or SO₃⁻;

R₄ represents H, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group, a substituted or unsubstituted acyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group;

X represents O, S, NH or CH₂; and

~~~~~ represents an  $\alpha$  bond or a  $\beta$  bond.

**PRELIMINARY AMENDMENT**  
National Stage Entry of PCT/JP03/08785  
Attorney Docket No.: Q85706

2. (original): The galactosamine derivative according to claim 1, wherein R<sub>1</sub> and R<sub>2</sub> each is H; R<sub>3</sub> is an acetyl group; R<sub>4</sub> is a substituted or unsubstituted aryl group; and R<sub>5</sub> is SO<sub>3</sub><sup>-</sup>.

3. (original): The galactosamine derivative according to claim 1, wherein R<sub>1</sub> is SO<sub>3</sub><sup>-</sup>; R<sub>2</sub> and R<sub>5</sub> each is H; R<sub>3</sub> is an acetyl group; and R<sub>4</sub> is a substituted or unsubstituted aryl group.

4. (original): The galactosamine derivative according to claim 1, wherein R<sub>1</sub> and R<sub>5</sub> each is H; R<sub>2</sub> is SO<sub>3</sub><sup>-</sup>; R<sub>3</sub> is an acetyl group; and R<sub>4</sub> is a substituted or unsubstituted aryl group.

5. (currently amended): A sulfotransferase inhibitor which comprises the galactosamine derivative according to ~~any one of claims 1 to 4~~ claim 1.

6. (original): The sulfotransferase inhibitor according to claim 5, which inhibits activity of a sulfotransferase having activity of transferring a sulfate group to a hydroxyl group bound to the 6-position carbon atom on the 4-sulfated galactosamine residue in the basic backbone of chondroitin sulfate.

7. (currently amended): A method for inhibiting activity of a sulfotransferase, which comprises allowing the galactosamine derivative according to ~~any one of claims 1 to 4~~ claim 1 to be present in an enzyme reaction system of the sulfotransferase.

8. (canceled).

9. (canceled).

**PRELIMINARY AMENDMENT**  
National Stage Entry of PCT/JP03/08785  
Attorney Docket No.: Q85706

10. (currently amended): A medicament based on inhibition of sulfotransferase activity, which comprises the galactosamine derivative according to ~~any one of claims 1 to 4~~ claim 1 as an active ingredient.

11. (currently amended): A medicament for treating or preventing diseases caused by acceleration of sulfotransferase activity, which comprises the galactosamine derivative according to ~~any one of claims 1 to 4~~ claim 1 as an active ingredient.

12. (new): A method for treating or preventing diseases caused by acceleration of sulfotransferase activity, which comprises administering to a subject in need thereof an effective amount of the galactosamine derivative according to claim 1.